S100A1 in human heart failure lack of recovery following left ventricular assist device support

Circulation: Heart Failure

Volumn 7, Issue 4, 2014, Pages 612-618

  Bennett, Mosi K ^a   Sweet, Wendy E ^a   Baicker McKee, Sara ^a   Looney, Elizabeth ^a   Karohl, Kristen ^a   Mountis, Maria ^a   Tang, W H Wilson ^a   Starling, Randall C ^a   Moravec, Christine S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adrenergic beta agonists; Calcium signaling; Heart failure; Heart assist devices

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); BETA ADRENERGIC RECEPTOR; ISOPRENALINE; PHOSPHOLAMBAN; PROTEIN; PROTEIN S100A1; RYANODINE RECEPTOR; UNCLASSIFIED DRUG; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; PROTEIN S 100; S100A1 PROTEIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CONVALESCENCE; FEMALE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONTRACTILITY; HUMAN; INOTROPISM; LEFT VENTRICULAR ASSIST DEVICE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE CONTRACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SARCOPLASMIC RETICULUM; CALCIUM SIGNALING; FOLLOW UP; HEART ASSIST DEVICE; HEART CONTRACTION; HEART MUSCLE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT FAILURE;

ADRENERGIC BETA AGONISTS; CALCIUM SIGNALING; HEART FAILURE; HEART-ASSIST DEVICES;

BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDIUM; RECOVERY OF FUNCTION; S100 PROTEINS; SARCOPLASMIC RETICULUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; TREATMENT FAILURE;

EID: 84907415999     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000849     Document Type: Article

References (50)

1. Houser SR, Margulies KB. Is depressed myocyte contractility centrally involved in heart failure? Circ Res. 2003;92:350-358.
2. Nass RD, Aiba T, Tomaselli GF, Akar FG. Mechanisms of disease: ion channel remodeling in the failing ventricle. Nat Clin Pract Cardiovasc Med. 2008;5:196-207.
3. Hadri L, Hajjar RJ. Calcium cycling proteins and their association with heart failure. Clin Pharmacol Ther. 2011;90:620-624.
4. Lompré AM, Hajjar RJ, Harding SE, Kranias EG, Lohse MJ, Marks AR. Ca2+ cycling and new therapeutic approaches for heart failure. Circulation. 2010;121:822-830.
5. Pleger ST, Most P, Boucher M, Soltys S, Chuprun JK, Pleger W, Gao E, Dasgupta A, Rengo G, Remppis A, Katus HA, Eckhart AD, Rabinowitz JE, Koch WJ. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation. 2007;115:2506-2515.
6. Kaye DM, Hoshijima M, Chien KR. Reversing advanced heart failure by targeting Ca2+ cycling. Annu Rev Med. 2008;59:13-28.
7. Vinge LE, Raake PW, Koch WJ. Gene therapy in heart failure. Circ Res. 2008;102:1458-1470.
8. Koitabashi N, Kass DA. Reverse remodeling in heart failure-mechanisms and therapeutic opportunities. Nat Rev Cardiol. 2012;9:147-157.
9. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, Borow K, Dittrich H, Zsebo KM, Hajjar RJ; Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-inhuman phase. clinical trial. J Card Fail. 2009;15:171-181.
10. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ; Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124:304-313.
11. Remppis A, Greten T, Schäfer BW, Hunziker P, Erne P, Katus HA, Heizmann CW. Altered expression of the Ca(2+)-binding protein S100A1 in human cardiomyopathy. Biochim Biophys Acta. 1996;1313:253-257.
12. Rohde D, Brinks H, Ritterhoff J, Qui G, Ren S, Most P. S100A1 gene therapy for heart failure: a novel strategy on the verge of clinical trials. J Mol Cell Cardiol. 2011;50:777-784.
13. Remppis A, Most P, Loffler E, Ehlermann P, Bernotat J, Pleger S, Borries M, Reppel M, Fischer J, Koch WJ, Smith G, Katus HA. The small EF-hand Ca2+ binding protein S100A1 increases contractility and Ca2+ cycling in rat cardiac myocytes. Basic Res Cardiol. 2002;97(suppl 1):56-62.
14. Most P, Remppis A, Pleger ST, Katus HA, Koch WJ. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am J Physiol Regul Integr Comp Physiol. 2007;293:R568-R577.
15. Brinks H, Rohde D, Voelkers M, Qiu G, Pleger ST, Herzog N, Rabinowitz J, Ruhparwar A, Silvestry S, Lerchenmüller C, Mather PJ, Eckhart AD, Katus HA, Carrel T, Koch WJ, Most P. S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol. 2011;58:966-973.
16. Most P, Bernotat J, Ehlermann P, Pleger ST, Reppel M, Börries M, Niroomand F, Pieske B, Janssen PM, Eschenhagen T, Karczewski P, Smith GL, Koch WJ, Katus HA, Remppis A. S100A1: a regulator of myocardial contractility. Proc Natl Acad Sci U S A. 2001;98:13889-13894.
17. Most P, Remppis A, Pleger ST, Löffler E, Ehlermann P, Bernotat J, Kleuss C, Heierhorst J, Ruiz P, Witt H, Karczewski P, Mao L, Rockman HA, Duncan SJ, Katus HA, Koch WJ. Transgenic overexpression of the Ca2+-binding protein S100A1 in the heart leads to increased in vivo myocardial contractile performance. J Biol Chem. 2003;278:33809-33817.
18. Völkers M, Loughrey CM, Macquaide N, Remppis A, DeGeorge BR Jr, Wegner FV, Friedrich O, Fink RH, Koch WJ, Smith GL, Most P. S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium. 2007;41:135-143.
19. Tsoporis JN, Marks A, Zimmer DB, McMahon C, Parker TG. The myocardial protein S100A1 plays a role in the maintenance of normal gene expression in the adult heart. Mol Cell Biochem. 2003;242:27-33.
20. Most P, Pleger ST, Völkers M, Heidt B, Boerries M, Weichenhan D, Löffler E, Janssen PM, Eckhart AD, Martini J, Williams ML, Katus HA, Remppis A, Koch WJ. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest. 2004;114:1550-1563.
21. Most P, Seifert H, Gao E, Funakoshi H, Völkers M, Heierhorst J, Remppis A, Pleger ST, DeGeorge BR Jr, Eckhart AD, Feldman AM, Koch WJ. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation. 2006;114:1258-1268.
22. Du XJ, Cole TJ, Tenis N, Gao XM, Köntgen F, Kemp BE, Heierhorst J. Impaired cardiac contractility response to hemodynamic stress in S100A1-deficient mice. Mol Cell Biol. 2002;22:2821-2829.
23. Pleger ST, Remppis A, Heidt B, Völkers M, Chuprun JK, Kuhn M, Zhou RH, Gao E, Szabo G, Weichenhan D, Müller OJ, Eckhart AD, Katus HA, Koch WJ, Most P. S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Mol Ther. 2005;12:1120-1129.
24. Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation. 1998;97:2316-2322.
25. Blaxall BC, Tschannen-Moran BM, Milano CA, Koch WJ. Differential gene expression and genomic patient stratification following left ventricular assist device support. J Am Coll Cardiol. 2003;41:1096-1106.
26. Hall JL, Fermin DR, Birks EJ, Barton PJ, Slaughter M, Eckman P, Baba HA, Wohlschlaeger J, Miller LW. Clinical, molecular, and genomic changes in response to a left ventricular assist device. J Am Coll Cardiol. 2011;57:641-652.
27. Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M, Banner NR, Khaghani A, Yacoub MH. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006;355:1873-1884.
28. Burkhoff D, Klotz S, Mancini DM. LVAD-induced reverse remodeling: basic and clinical implications for myocardial recovery. J Card Fail. 2006;12:227-239.
29. Xydas S, Rosen RS, Ng C, Mercando M, Cohen J, DiTullio M, Magnano A, Marboe CC, Mancini DM, Naka Y, Oz MC, Maybaum S. Mechanical unloading leads to echocardiographic, electrocardiographic, neurohormonal, and histologic recovery. J Heart Lung Transplant. 2006;25:7-15.
30. Maybaum S, Mancini D, Xydas S, Starling RC, Aaronson K, Pagani FD, Miller LW, Margulies K, McRee S, Frazier OH, Torre-Amione G; LVAD Working Group. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation. 2007;115:2497-2505.
31. Klotz S, Jan Danser AH, Burkhoff D. Impact of left ventricular assist device (LVAD) support on the cardiac reverse remodeling process. Prog Biophys Mol Biol. 2008;97:479-496.
32. Ogletree ML, Sweet WE, Talerico C, Klecka ME, Young JB, Smedira NG, Starling RC, Moravec CS. Duration of left ventricular assist device support: effects on abnormal calcium cycling and functional recovery in the failing human heart. J Heart Lung Transplant. 2010;29:554-561.
33. Ogletree-Hughes ML, Stull LB, Sweet WE, Smedira NG, McCarthy PM, Moravec CS. Mechanical unloading restores beta-adrenergic responsiveness and reverses receptor downregulation in the failing human heart. Circulation. 2001;104:881-886.
34. Moravec CS, Schluchter MD, Paranandi L, Czerska B, Stewart RW, Rosenkranz E, Bond M. Inotropic effects of angiotensin II on human cardiac muscle in vitro. Circulation. 1990;82:1973-1984.
35. Sprung J, Ogletree-Hughes ML, McConnell BK, Zakhary DR, Smolsky SM, Moravec CS. The effects of propofol on the contractility of failing and nonfailing human heart muscles. Anesth Analg. 2001;93:550-559.
36. DiPaola NR, Sweet WE, Stull LB, Francis GS, Schomisch Moravec C. Beta-adrenergic receptors and calcium cycling proteins in non-failing, hypertrophied and failing human hearts: transition from hypertrophy to failure. J Mol Cell Cardiol. 2001;33:1283-1295.
37. Dash R, Frank KF, Carr AN, Moravec CS, Kranias EG. Gender influences on sarcoplasmic reticulum Ca2+-handling in failing human myocardium. J Mol Cell Cardiol. 2001;33:1345-1353.
38. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205-211.
39. Ehlermann P, Remppis A, Guddat O, Weimann J, Schnabel PA, Motsch J, Heizmann CW, Katus HA. Right ventricular upregulation of the Ca(2+) binding protein S100A1 in chronic pulmonary hypertension. Biochim Biophys Acta. 2000;1500:249-255.
40. Frazier OH, Benedict CR, Radovancevic B, Bick RJ, Capek P, Springer WE, Macris MP, Delgado R, Buja LM. Improved left ventricular function after chronic left ventricular unloading. Ann Thorac Surg. 1996;62: 675-681; discussion 681.
41. Bartling B, Milting H, Schumann H, Darmer D, Arusoglu L, Koerner MM, El-Banayosy A, Koerfer R, Holtz J, Zerkowski HR. Myocardial gene expression of regulators of myocyte apoptosis and myocyte calcium homeostasis during hemodynamic unloading by ventricular assist devices in patients with end-stage heart failure. Circulation. 1999;100(suppl II):II216-II223.
42. Heerdt PM, Holmes JW, Cai B, Barbone A, Madigan JD, Reiken S, Lee DL, Oz MC, Marks AR, Burkhoff D. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation. 2000;102:2713-2719.
43. Hasenfuss G, Reinecke H, Studer R, Meyer M, Pieske B, Holtz J, Holubarsch C, Posival H, Just H, Drexler H. Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ Res. 1994;75:434-442.
44. Klotz S, Barbone A, Reiken S, Holmes JW, Naka Y, Oz MC, Marks AR, Burkhoff D. Left ventricular assist device support normalizes left and right ventricular beta-adrenergic pathway properties. J Am Coll Cardiol. 2005;45:668-676.
45. Kato TS, Chokshi A, Singh P, Khawaja T, Cheema F, Akashi H, Shahzad K, Iwata S, Homma S, Takayama H, Naka Y, Jorde U, Farr M, Mancini DM, Schulze PC. Effects of continuous-flow versus pulsatile-flow left ventricular assist devices on myocardial unloading and remodeling. Circ Heart Fail. 2011;4:546-553.
46. Thohan V, Stetson SJ, Nagueh SF, Rivas-Gotz C, Koerner MM, Lafuente JA, Loebe M, Noon GP, Torre-Amione G. Cellular and hemodynamics responses of failing myocardium to continuous flow mechanical circulatory support using the DeBakey-Noon left ventricular assist device: a comparative analysis with pulsatile-type devices. J Heart Lung Transplant. 2005;24:566-575.
47. Birks EJ, George RS, Hedger M, Bahrami T, Wilton P, Bowles CT, Webb C, Bougard R, Amrani M, Yacoub MH, Dreyfus G, Khaghani A. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation. 2011;123:381-390.
48. Garcia S, Kandar F, Boyle A, Colvin-Adams M, Lliao K, Joyce L, John R. Effects of pulsatile-and continuous-flow left ventricular assist devices on left ventricular unloading. J Heart Lung Transplant. 2008; 27:261-267.
49. Krabatsch T, Schweiger M, Dandel M, Stepanenko A, Drews T, Potapov E, Pasic M, Weng YG, Huebler M, Hetzer R. Is bridge to recovery more likely with pulsatile left ventricular assist devices than with nonpulsatileflow systems? Ann Thorac Surg. 2011;91:1335-1340.
50. Ambardekar AV, Walker JS, Walker LA, Cleveland JC Jr, Lowes BD, Buttrick PM. Incomplete recovery of myocyte contractile function despite improvement of myocardial architecture with left ventricular assist device support. Circ Heart Fail. 2011;4:425-432.